Immunovia Ab · OMXSTO:IMMNOV
Immunovia Ab — Jefferies Virtual London Healthcare Conference 2020
20 slides from Immunovia Ab's conference presentation, Nov 18, 2020
Slide 1: Immunovia Investor Presentation
Immunovia Investor Presentation Jefferies Virtual London Healthcare Conference November 18th, 2020
Slide 2: Forward Looking Statements
Forward Looking Statements IMPORTANT: The following applies to this document, the oral presentation of the information in this document by Immunovia AB (publ) (the “Company”) or any person on behalf of the Company, and any question-and-answer session that follows the oral presentation (collectively,
Slide 3: Presenter Patrik Dahlen
Presenter Patrik Dahlen CEO of Immunovia 3
Slide 4: Immunovia Key Investment Highlights
Immunovia Key Investment Highlights First Mover Advantage with IMMrayTM PanCan–d Proprietary Blood-Based Biomarker IMMray™ Platform Technology Platform Significant Unmet Medical Need for Initial Addressable Market Size (EU/US) Early Detection of Pancreatic Cancer ~$4.4 Bn (USD) First-To-Market Oppor
Slide 5: Company Overview
Company Overview Listed on NASDAQ Stockholm (ticker IMMNOV) Commercial Testing Product Discovery & Development Research > 20 Years World renowned Translational Cancer Center IP-rights for IMMray™ platform tests transferred to Immunovia AB. 5
Slide 6: Differentiated Technology Platform: IMMray
Differentiated Technology Platform: IMMray™ Patient Sample Testing In The Lab 6
Slide 7: Significant Unmet Medical Need
Significant Unmet Medical Need Early Detection of Pancreatic Cancer ~50% Five Year Survival <5% Early Diagnosis In Pancreatic Cancer Is The Today >80% Late Diagnosis Only Hope 4.6 Months Median Survival Someone Diagnosed With Pancreatic Cancer In Europe 7
Slide 8: IMMray PanCan-d Targeting Three High-Risk Groups
IMMray™ PanCan-d Targeting Three High-Risk Groups Early/ Hereditary Concerning NOD Familial symptoms • Familial autosomal ≥ 2 close • Depression • New onset diabetes type II fam members • Indigestion/Nausea after 50 years of age • Familiar non-autosomal ≥ 3 • Jaundice • 8-10 times increased risk of
Slide 9: IMMray PanCan-d Targets Initial Addressable Market of ~$4.4bn in US/EU
IMMray™ PanCan-d Targets Initial Addressable Market of ~$4.4bn (USD) in US/EU 9
Slide 10: IMMray PanCan-d Commercial Test Model Study
IMMray™ PanCan-d Commercial Test Model Study Confirmed Results from Optimization Study with Accuracies ~95% for Diagnosing Pancreatic Cancer vs All Controls 10
Slide 11: IMMray PanCan-d Clinical Verification Study
IMMray™ PanCan-d Clinical Verification Study IMMray™ PanCan-d test for PDAC vs. non-PDAC controls (including healthy and symptomatic controls Study Design New independent samples cohorts run according to product configuration, locked IMMray™ PanCan-d signature and model cut off. Using verified SW, l
Slide 12: The Road to Sales Start Q1 2021
The Road to Sales Start Q1 2021 Subsequent Testing in Q2 2021 We Are Here Sales Start Q1 2021 with Subsequent Testing Q2 2021 12
Slide 13: IMMray PanCan-d Road to Market Timeline
IMMrayTM PanCan-d Road to Market Timeline IMMray™ PanCan-d Q1 2021 With Subsequent Testing in Q2 2021 PROSPECTIVE CLINICAL STUDIES REIMBURSED SALES RETROSPECTIVE /OPTIMIZATION/VALIDATION SELF PAY-SALES ACCREDITATIONS CONFIRMATORY MARKET EXPANSION STUDIES 2013 - 2019 2020-2022 2023- 13
Slide 14: IMMray PanCan-d Launch Regions by Priority
IMMray™ PanCan-d Launch Regions by Priority 1st Wave US Commercialization 2nd Wave Europe Commercialization Sweden/Nordic UK Spain / Italy DACH Benelux France Canada Countries with prospective site centers, PanFAM, PanSYM, PanDIA, familial pancreatic screening programs, diagnostic/GI centers and pri
Slide 15: The Path to Market
The Path to Market Main programs Target Key Customers in Priority Geographies Reimbursement Immunovia Dx - Reference labs (EU/US) Laboratories - Guidance Experts - Cancer Centre Clinicians - Health Economic Studies - Private/Public Centre Clinical Studies - Private/Public Insurance Clinicians Progra
Slide 16: World's Largest Key Opinion Leader Network
World’s Largest Key Opinion Leader Network (US & Europe) North America Europe Montreal, CA SWEDEN Research Institute of the Umeå University Hospital McGill University Health Karolinska Institute Center (RI-MUHC) Linköping University Massachusetts Hospital Massachusetts General Sahlgrenska University
Slide 17: Global Collaborations with Pancreatic Cancer Patient Organizations
Global Collaborations with Pancreatic Cancer Patient Organizations North America Europe Canada SWEDEN Pancreatic Cancer Canada Palema Nätverket mot cancer USA Lustgarten Foundation NORWAY The Pancreatic Cancer Action Network Pancreaskreft Nettverk (PanCAN) The World Pancreatic Cancer Coalition DENMA
Slide 18: Pipeline Studies: Lung Cancer & Rheumatoid Arthritis
Pipeline Studies: Lung Cancer & Rheumatoid Arthritis IMMrayTM PanCan-d to Market Lung Cancer Aims Rheumatoid Arthritis Aims for for Early Diagnosis Accurate Detection 18
Slide 19: IMMray PanCan-d US Sales Start Q1 2021
IMMrayTM PanCan-d US Sales Start Q1 2021 Immunovia's vision is to dominate the pancreatic cancer diagnostics market First To Market Solution For Early Detection Of Pancreatic Cancer – Addressable Market Opportunity of $4 Billion USD IMMrayTM PanCan-D Sales Start in Q1 2021 with Subsequent Testing in
Slide 20: Thank you!
Julie Silber Director of Investor Relations Immunovia AB Mobile: +46(0)79 3486277 julie.silber@immunovia.com www.immunovia.com
Immunovia — Jefferies Virtual London Healthcare Conference 2020 on 6ix